Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone in mCRPC post-docetaxel
NCT01795703Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started Jun 2012; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01795703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01795703.